Dr Cyrus Ali, MD | |
1630 Hospital Dr, Suite 240, Santa Fe, NM 87505-4772 | |
(505) 913-3975 | |
(505) 986-8001 |
Full Name | Dr Cyrus Ali |
---|---|
Gender | Male |
Speciality | General Surgery |
Experience | 21 Years |
Location | 1630 Hospital Dr, Santa Fe, New Mexico |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1831374610 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | MD2009-0197 (New Mexico) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
St Luke's Regional Medical Center | Boise, ID | Hospital |
St Luke's Nampa Medical Center | Nampa, ID | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
St Lukes Clinic-treasure Valley Llc | 4981878402 | 968 |
News Archive
Beyond the legal challenges, a major new hurdle is emerging for the health care reform law. Recent studies show that the major players in the health care marketplace - insurers, hospitals and physician practices - are consolidating, which increases the likelihood they will collude on prices charged to employers and to consumers and defeat cost control measures in the law.
The 2009 costs of antibiotics covered by private insurance companies in the U.S. for children younger than 10 years old were estimated to be more than five times higher than the costs in the United Kingdom (U.K.), which are covered by a government universal health plan.
New research from the Centers for Disease Control and Prevention (CDC) journal Emerging Infectious Diseases analyzed a case showing in-flight transmission of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) despite passengers getting tested before departing to New Zealand.
Vanda Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee voted overwhelmingly to recommend the approval of Vanda's New Drug Application for tasimelteon, proposed tradename HETLIOZ™, for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind.
Oncothyreon Inc. today announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.
› Verified 9 days ago
Entity Name | St Lukes Clinic-treasure Valley Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1326336058 PECOS PAC ID: 4981878402 Enrollment ID: O20111119000045 |
News Archive
Beyond the legal challenges, a major new hurdle is emerging for the health care reform law. Recent studies show that the major players in the health care marketplace - insurers, hospitals and physician practices - are consolidating, which increases the likelihood they will collude on prices charged to employers and to consumers and defeat cost control measures in the law.
The 2009 costs of antibiotics covered by private insurance companies in the U.S. for children younger than 10 years old were estimated to be more than five times higher than the costs in the United Kingdom (U.K.), which are covered by a government universal health plan.
New research from the Centers for Disease Control and Prevention (CDC) journal Emerging Infectious Diseases analyzed a case showing in-flight transmission of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) despite passengers getting tested before departing to New Zealand.
Vanda Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee voted overwhelmingly to recommend the approval of Vanda's New Drug Application for tasimelteon, proposed tradename HETLIOZ™, for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind.
Oncothyreon Inc. today announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Cyrus Ali, MD 1630 Hospital Dr, Suite 240, Santa Fe, NM 87505-4772 Ph: (505) 913-3975 | Dr Cyrus Ali, MD 1630 Hospital Dr, Suite 240, Santa Fe, NM 87505-4772 Ph: (505) 913-3975 |
News Archive
Beyond the legal challenges, a major new hurdle is emerging for the health care reform law. Recent studies show that the major players in the health care marketplace - insurers, hospitals and physician practices - are consolidating, which increases the likelihood they will collude on prices charged to employers and to consumers and defeat cost control measures in the law.
The 2009 costs of antibiotics covered by private insurance companies in the U.S. for children younger than 10 years old were estimated to be more than five times higher than the costs in the United Kingdom (U.K.), which are covered by a government universal health plan.
New research from the Centers for Disease Control and Prevention (CDC) journal Emerging Infectious Diseases analyzed a case showing in-flight transmission of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) despite passengers getting tested before departing to New Zealand.
Vanda Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee voted overwhelmingly to recommend the approval of Vanda's New Drug Application for tasimelteon, proposed tradename HETLIOZ™, for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind.
Oncothyreon Inc. today announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.
› Verified 9 days ago
Poseidon Spyros Varvitsiotis, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1631 Hospital Dr, Santa Fe, NM 87505 Phone: 505-988-3975 Fax: 505-986-8001 | |
William Edgefield Mitchell Jr., MD Surgery Medicare: Medicare Enrolled Practice Location: 9a Rocky Slope Dr, Santa Fe, NM 87508 Phone: 505-473-3648 | |
Dara Vahid, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 61 Calle Encanto, Santa Fe, NM 87506 Phone: 505-984-0754 | |
Anna M Voltura, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 435 Saint Michaels Dr Ste 104, Santa Fe, NM 87505 Phone: 505-372-1052 Fax: 505-820-3172 | |
John Dirk Wassner, MD Surgery Medicare: Medicare Enrolled Practice Location: 465 Saint Michaels Dr, Suite 110, Santa Fe, NM 87505 Phone: 505-954-8720 | |
Kimberly Ann Moseley, MD Surgery Medicare: Medicare Enrolled Practice Location: 455 Saint Michaels Dr, Santa Fe, NM 87505 Phone: 505-913-3975 | |
Joseph M. Smith Iii, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 490b W Zia Rd, Suite A, Santa Fe, NM 87505 Phone: 505-995-8346 Fax: 505-995-8345 |